The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 19, 2024
Filed:
Nov. 29, 2018
Applicant:
Idorsia Pharmaceuticals Ltd, Allschwil, CH;
Inventors:
Assignee:
IDORSIA PHARMACEUTICALS LTD, Allschwil, CH;
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/506 (2006.01); A61K 9/00 (2006.01); A61K 9/20 (2006.01); A61K 31/7004 (2006.01); A61K 31/7048 (2006.01); A61P 3/10 (2006.01); A61P 7/00 (2006.01); A61P 13/12 (2006.01);
U.S. Cl.
CPC ...
A61K 31/506 (2013.01); A61K 9/0053 (2013.01); A61K 9/2018 (2013.01); A61K 9/2054 (2013.01); A61K 31/7004 (2013.01); A61K 31/7048 (2013.01); A61P 3/10 (2018.01); A61P 7/00 (2018.01); A61P 13/12 (2018.01);
Abstract
The present invention concerns the compound aprocitentan, {5-(4-bromo-phenyl)-6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl}-sulfamide: and its use as endothelin receptor antagonist, in combination with an SGLT-2 inhibitor. The invention further relates to pharmaceutical compositions comprising aprocitentan in combination with said SGLT-2 inhibitor. The invention further relates to such pharmaceutical compositions comprising crystalline forms of aprocitentan.